Similar to our findings, a study with glucose-lowering using liraglutide, sulfonylurea and/or insulin showed a reduction in renal parenchyma volume in patients with type 2 diabetes after 26 weeks of treatment; however, they did not find a superior effect of liraglutide after adjusting for baseline volume [29]. Here, INS is linked to type 2 diabetes mellitus.